Ionix: Eye on peripheral pain
Going through the list of compounds in the clinic to treat pain is a depressing exercise. With the exception of the COX-2 inhibitors and novel ways to deliver opioids, few new approaches have been seen in the past 50 years or more. Ionix Pharmaceuticals Ltd. is stepping into that space with a focus on treatments for inflammatory and neuropathic pain that block peripheral nervous system targets, hoping for selective efficacy without CNS side effects.
The formation of the company marks the